Literature DB >> 30195018

Schisandrin B exhibits potent anticancer activity in triple negative breast cancer by inhibiting STAT3.

Xuanxuan Dai1, Changtian Yin1, Guilong Guo2, Yi Zhang3, Chenguang Zhao4, Jianchang Qian4, Ouchen Wang2, Xiaohua Zhang5, Guang Liang6.   

Abstract

Triple negative breast cancer (TNBC) is an aggressive subgroup of human breast cancer. In this study, we have examined the potential of Schisandrin B (Sch B), a bioactive chemical compound found in Schisandra chinensis, against TNBC. We used MDA-MB-231, BT-549, and MDA-MB-468 TNBC cells and immunodeficient mice to study the effect of Sch B. Our results show that Sch B inhibits TNBC growth by inducing cell cycle arrest and by triggering apoptotic death. Sch B also inhibited the migration and colony formation of tumor cells, and prevented the growth of TNBC cells in mice. We found that these inhibitory activities were mediated through suppression of signal transducer and activator of transcription-3 (STAT3) phosphorylation and nuclear translocation. Taken together, our studies show that Sch B has potent anti-tumor activity against TNBC via a novel mechanism involving STAT3 inactivation.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Apoptosis; STAT3; Schisandrin B; Triple negative breast cancer

Mesh:

Substances:

Year:  2018        PMID: 30195018     DOI: 10.1016/j.taap.2018.09.005

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  7 in total

Review 1.  Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress- and aging-related diseases.

Authors:  Alexander G Panossian; Thomas Efferth; Alexander N Shikov; Olga N Pozharitskaya; Kenny Kuchta; Pulok K Mukherjee; Subhadip Banerjee; Michael Heinrich; Wanying Wu; De-An Guo; Hildebert Wagner
Journal:  Med Res Rev       Date:  2020-10-25       Impact factor: 12.944

Review 2.  Potential of Schisandra chinensis (Turcz.) Baill. in Human Health and Nutrition: A Review of Current Knowledge and Therapeutic Perspectives.

Authors:  Adriana Nowak; Małgorzata Zakłos-Szyda; Janusz Błasiak; Agnieszka Nowak; Zhuo Zhang; Bolin Zhang
Journal:  Nutrients       Date:  2019-02-04       Impact factor: 5.717

Review 3.  A Comprehensive Review on Schisandrin B and Its Biological Properties.

Authors:  M I Nasser; Shuoji Zhu; Chen Chen; Mingyi Zhao; Huanlei Huang; Ping Zhu
Journal:  Oxid Med Cell Longev       Date:  2020-03-14       Impact factor: 6.543

4.  Schisandrin B suppresses osteosarcoma lung metastasis in vivo by inhibiting the activation of the Wnt/β‑catenin and PI3K/Akt signaling pathways.

Authors:  Yuping Wang; Jin Chen; Yanran Huang; Shengdong Yang; Tao Tan; Nan Wang; Jun Zhang; Caihong Ye; Mengqi Wei; Jinyong Luo; Xiaoji Luo
Journal:  Oncol Rep       Date:  2022-01-14       Impact factor: 3.906

5.  Schisandrin B Induced ROS-Mediated Autophagy and Th1/Th2 Imbalance via Selenoproteins in Hepa1-6 Cells.

Authors:  Siran Tan; Zhi Zheng; Tianqi Liu; Xiaoyun Yao; Miao Yu; Yubin Ji
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 8.786

6.  The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts.

Authors:  Yan Zhong; Lin Deng; Shuo Shi; Qiu-Yao Huang; Shu-Min Ou-Yang; Jian-Shan Mo; Kai Zhu; Xin-Ming Qu; Pei-Qing Liu; Yuan-Xiang Wang; Xiao-Lei Zhang
Journal:  Acta Pharmacol Sin       Date:  2021-07-15       Impact factor: 6.150

Review 7.  Inflammation suppression in doxorubicin-induced cardiotoxicity: natural compounds as therapeutic options.

Authors:  Fatemeh Yarmohammadi; Hedyieh Karbasforooshan; A Wallace Hayes; Gholamreza Karimi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-08-05       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.